Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Affimed GmbH currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These cases are distributed across 4 distinct examiners and an equal number of distinct art units. This distribution shows that every active matter is being handled by a different examiner in a unique art unit, indicating a broad spread of technical subject matter across the USPTO's pharmaceutical divisions.
PRIEST, JESSICA MARIE is the busiest examiner for the company with 1 pending office action. Because the total pending office actions are spread among several distinct examiners, the company must manage multiple separate prosecution tracks simultaneously. For the practitioner, this means there is no central examiner or art unit to focus on, necessitating a strategy that addresses the specific preferences and examination styles of various distinct art units. Success depends on maintaining consistent technical arguments while adapting to the individual requirements of each assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293307 | DUPLEXBODIES | PRIEST, JESSICA MARIE | — |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17807211 | METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT | KIM, YUNSOO | 3d overdue |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | — |
| 17177052 | Cryopreserved NK cells preloaded with an antibody construct | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1641 | 1 |
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293307 | DUPLEXBODIES | PRIEST, JESSICA MARIE | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | 1641 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17807211 | METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT | KIM, YUNSOO | 1674 | §112 | Final Rejection | 3d overdue | Pending | Jun 16, 2022 |
| 17177052 | Cryopreserved NK cells preloaded with an antibody construct | GUSTILO, ESTELLA M | 1646 | §103Other | Final Rejection | — | Pending | Feb 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAffimed GmbH has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jessica Marie Priest has the most, with 1 of Affimed GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
